SynthesisNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Prognostic value of neurofilament light chain protein and glial fibrillary acidic protein in multiple sclerosis subtypes and disease activity patterns: a systematic review and meta-analysis.
Synthesis in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeurofilament light chain protein and glial fibrillary acidic protein have been proposed as potential blood biomarkers for multiple sclerosis. However, their diagnostic and prognostic values across different subtypes and disease activity patterns remain unclear.
methodsWe systematically searched major databases (inception to February 13, 2025). A total of thirteen studies including 4,016 individuals were incorporated. A random-effects meta-analysis methodology was applied to assess the forecasting capabilities of NfL and GFAP concerning multiple sclerosis relapses and the advancement of disability. Subgroup examinations were executed according to disease classifications and the observed activity levels.
resultsTreated as a continuous measure, NfL exhibited a 4% increase in risk for adverse events with each individual unit escalation (RR = 1.04, 95% CI: 1.01-1.06, P < 0.001). Subgroup analyses revealed that predictive power was stronger in RRMS compared with mixed type (RR = 3.82 vs. 1.03, P < 0.01), and was statistically significant for neurodegenerative progression (EDSS worsening without inflammation) (RR = 1.03, P < 0.05). Using a threshold, NfL levels above the cutoff increased risk 2.61-fold (RR = 2.61, 95% CI: 1.74-3.92). GFAP showed no significant overall prognostic value (RR = 1.01, P = 0.18), with no subgroup differences.
conclusionNfL is a sensitive biomarker for RRMS and neurodegenerative progression, with its value dependent on subtype and activity pattern. No evidence supports GFAP as an independent prognostic marker. Precise MS subtyping is crucial for clinical biomarker application.
Indexed as
Identifiers
42322442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.